Ref003 04 Immunology

<<< Refs

2 May 2020

 

Agrawal 2016

Agrawal AS, Tao X, Algaissi A, et al. Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung im-munopathology on challenge with live virus. Hum Vaccin Immunother. 2016 Sep;12(9):2351-6. PubMed: https://pubmed.gov/27269431. Full-text: https://doi.org/10.1080/21645515.2016.1177688

Amanat 2020

Amanat F, Krammer F. SARS-CoV-2 Vaccines: Status Report. Immunity. 2020 Apr 14;52(4):583-589. PubMed: https://pubmed.gov/32259480. Full-text: https://doi.org/10.1016/j.immuni.2020.03.007

Bloch 2020

Bloch EM, Shoham S, Casadevall A, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020 Apr 7. pii: 138745. PubMed: https://pubmed.gov/32254064. Full-text: https://doi.org/138745

Bolles 2011

Bolles M, Deming D, Long K, et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J Virol. 2011 Dec;85(23):12201-15. PubMed: https://pubmed.gov/21937658. Full-text: https://doi.org/10.1128/JVI.06048-11

Casadevall 2004

Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nat Rev Microbiol. 2004 Sep;2(9):695-703. PubMed: https://pubmed.gov/15372080. Full-text: https://doi.org/10.1038/nrmicro974

Castilow

Castilow EM, Olson MR, Varga SM. Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease. Immunol Res. 2007;39(1-3):225-39. Pub-Med: https://pubmed.gov/17917067. Full-text: https://doi.org/10.1007/s12026-007-0071-6

Chun 2016

Chun S, Chung CR, Ha YE, et al. Possible Transfusion-Related Acute Lung Injury Following Convalescent Plasma Transfusion in a Patient With Middle East Respiratory Syndrome. Ann Lab Med. 2016 Jul;36(4):393-5. PubMed: https://pubmed.gov/27139619. Full-text: https://doi.org/10.3343/alm.2016.36.4.393

Deming 2006

Deming D, Sheahan T, Heise M, et al. Vaccine efficacy in senescent mice chal-lenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med. 2006 Dec;3(12):e525. PubMed: https://pubmed.gov/17194199. Full-text: https://doi.org/10.1371/journal.pmed.0030525

Honda-Okubo 2015

Honda-Okubo Y, Barnard D, Ong CH, Peng BH, Tseng CT, Petrovsky N. Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology. J Virol. 2015 Mar;89(6):2995-3007. PubMed: https://pubmed.gov/25520500. Full-text: https://doi.org/10.1128/JVI.02980-14

Houser 2017

Houser KV, Broadbent AJ, Gretebeck L, et al. Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody. PLoS Pathog. 2017 Aug 17;13(8):e1006565. PubMed: https://pubmed.gov/28817732. Full-text: https://doi.org/10.1371/journal.ppat.1006565

Iwata-Yoshikawa 2014

Iwata-Yoshikawa N, Uda A, Suzuki T, et al. Effects of Toll-like receptor stimula-tion on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine. J Virol. 2014 Aug;88(15):8597-614. PubMed: https://pubmed.gov/24850731. Full-text: https://doi.org/10.1128/JVI.00983-14

Jaume 2011

Jaume M, Yip MS, Cheung CY, et al. Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent FcgammaR pathway. J Vi-rol. 2011 Oct;85(20):10582-97. PubMed: https://pubmed.gov/21775467. Full-text: https://doi.org/10.1128/JVI.00671-11

Kim 2020

Kim YI, Kim SG, Kim SM, et al. Infection and Rapid Transmission of SARS-CoV-2 in Ferrets. Cell Host Microbe. 2020 Apr 5. pii: S1931-3128(20)30187-6. PubMed: https://pubmed.gov/32259477. Full-text: https://doi.org/10.1016/j.chom.2020.03.023

Liu 2019

Liu L, Wei Q, Lin Q, et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight. 2019 Feb 21;4(4). pii: 123158. PubMed: https://pubmed.gov/30830861. Full-text: https://doi.org/123158

Lokugamage 2008

Lokugamage KG, Yoshikawa-Iwata N, Ito N, et al. Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV. Vaccine. 2008 Feb 6;26(6):797-808. PubMed: https://pubmed.gov/18191004. Full-text: https://doi.org/10.1016/j.vaccine.2007.11.092

Mair-Jenkins 2015

Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of conva-lescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015 Jan 1;211(1):80-90. PubMed: https://pubmed.gov/25030060. Full-text: https://doi.org/10.1093/infdis/jiu396

Marston 2018

Marston HD, Paules CI, Fauci AS. Monoclonal Antibodies for Emerging Infectious Diseases – Borrowing from History. N Engl J Med. 2018 Apr 19;378(16):1469-1472. PubMed: https://pubmed.gov/29513615. Full-text: https://doi.org/10.1056/NEJMp1802256

Openshaw 2001

Openshaw PJ, Culley FJ, Olszewska W. Immunopathogenesis of vaccine-enhanced RSV disease. Vaccine. 2001 Oct 15;20 Suppl 1:S27-31. PubMed: https://pubmed.gov/11587806. Full-text: https://doi.org/10.1016/s0264-410x(01)00301-2

Pedersen 1983

Pedersen NC, Black JW. Attempted immunization of cats against feline infec-tious peritonitis, using avirulent live virus or sublethal amounts of virulent virus. Am J Vet Res. 1983 Feb;44(2):229-34 PubMed: https://pubmed.gov/6299143.

Perlman 2005

Perlman S, Dandekar AA. Immunopathogenesis of coronavirus infections: impli-cations for SARS. Nat Rev Immunol. 2005 Dec;5(12):917-27. PubMed: https://pubmed.gov/16322745. Full-text: https://doi.org/10.1038/nri1732

Tseng

Tseng CT, Sbrana E, Iwata-Yoshikawa N, et al. Immunization with SARS coro-navirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One. 2012;7(4):e35421. PubMed: https://pubmed.gov/22536382. Full-text: https://doi.org/10.1371/journal.pone.0035421

Vennema

Vennema H, de Groot RJ, Harbour DA, et al. Immunogenicity of recombinant feline infectious peritonitis virus spike protein in mice and kittens. Adv Exp Med Biol. 1990;276:217-22. PubMed: https://pubmed.gov/1966406. Full-text: https://doi.org/10.1007/978-1-4684-5823-7_30

Wang 2016

Wang Q, Zhang L, Kuwahara K, et al. Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates. ACS Infect Dis. 2016 May 13;2(5):361-76. PubMed: https://pubmed.gov/27627203. Full-text: https://doi.org/10.1021/acsinfecdis.6b00006

Weingartl 2004

Weingartl H, Czub M, Czub S, et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol. 2004 Nov;78(22):12672-6. PubMed: https://pubmed.gov/15507655. Full-text: https://doi.org/10.1128/JVI.78.22.12672-12676.2004

Weiss

Weiss RC, Scott FW. Antibody-mediated enhancement of disease in feline infectious peritonitis: comparisons with dengue hemorrhagic fever. Comp Immunol Microbiol Infect Dis. 1981;4(2):175-89. PubMed: https://pubmed.gov/6754243. Full-text: https://doi.org/10.1016/0147-9571(81)90003-5

Yang 2005

Yang ZY, Werner HC, Kong WP, et al. Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):797-801. PubMed: https://pubmed.gov/15642942. Full-text: https://doi.org/10.1073/pnas.0409065102

Yasui 2008

Yasui F, Kai C, Kitabatake M, et al. Prior immunization with severe acute res-piratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucle-ocapsid protein causes severe pneumonia in mice infected with SARS-CoV. J Immunol. 2008 Nov 1;181(9):6337-48. PubMed: https://pubmed.gov/18941225. Full-text: https://doi.org/10.4049/jimmunol.181.9.6337